Prediction Case File
YouTubeTracking Live

IRTC Stock Crash: iRhythm Plunges 30% After Q3 Earnings Miss & Zio MCT Delay

1 extracted signal · 0 resolved · 1 still active

Global News Daily profile imageGlobal News DailyIndependent analyst profile
Source published
08 Nov 2026, 10:37 UTC
Recorded by Tahlil Plus
08 Nov 2026, 14:19 UTC
Video preview for IRTC Stock Crash: iRhythm Plunges 30% After Q3 Earnings Miss & Zio MCT Delay
Source overview

AI-generated source summary

iRhythm Technologies experienced a severe 30.44% single-session sell-off, plunging to $90.22 following an unexpected FDA audit request regarding packaging design controls and customer notifications. Despite this headline overhang and a negative operating loss of $56.2 million driven by aggressive R&D and legal remediation, the company maintains robust fundamentals with $558.4 million in trailing 12-month revenue, an impressive 67.8% gross margin, and a comfortable 3.5 to 4-year cash runway. The core technological moat rests on the Zio platform's 14-day continuous AI-integrated monitoring and its proprietary Zeus AI system trained on 1 billion hours of ECG data. Three probabilistic future scenarios are modelled: a base case (50% probability) targeting $110-$125 over 6-9 months assuming FDA inquiries resolve; a bull case (30% probability) targeting $145-$165 driven by rapid international expansion in Japan; and a bear case (20% probability) targeting $65-$75 if regulatory friction escalates. Overall, the stock is classified as a speculative contrarian buy, heavily dependent on the formal issuance of the FDA inspection close-out letter (EIR) to unlock shareholder value.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

Global News Daily

Platform-wide history, separate from this source evaluation.

Reliability
41.2
Tracked signals
99
Historical success
25.0%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail